Medicalgorithmics a Warsaw Stock Exchange listed medical technology company, is boosting its sales capabilities in North America with the appointment of James Landis as the new Vice President of Sales and Business Development for North America. The move is aimed at accelerating long-term growth and increasing market share. James brings 20 years of extensive experience in sales and business development roles specifically in the cardiac monitoring space in the US. At Medicalgorithmics, he will be responsible for strengthening client relationships, expanding distribution channels, and developing sales growth initiatives for the North American market, particularly in the United States.
“The US market is a strategic priority for Medicalgorithmics. The arrival of James Landis clearly demonstrates that we are committed to US growth and is the next milestone in achieving our US market expansion strategy presented in December 2022. James has vast experience and a deep understanding of the medical technology industry, including cardiac monitoring services. He is a major strategic asset for our operations in North America and will play a vital role in pursuing our growth strategy,” says Jaroslaw Jerzakowski, Medicalgorithmics Chief Commercial Officer.
“I am thrilled to be joining Medicalgorithmics, a software company with a long history of providing best in class cardiac rhythm analysis. I look forward to building the North American market and expanding the reach of Medicalgorithmics’ technology,” says James Landis, Medicalgorithmics Vice President of Sales and Business Development for North America.
James’s appointment will support Medicalgorithmics strategic objectives for the US market outlined in December 2022.
The strategy aims to provide the full scope of the company’s services, including access to the company’s advanced AI algorithms as well as the PocketECG software platform. We will also be granting licenses for the use of our software, including our advanced algorithms rendered on a non-exclusive basis. The strategy also seeks to reach new sales channels, ultimately increasing revenue by offering services to a larger number of patients and providing additional opportunities for growth in launching new services. This will enable diversification through cooperation with distributors as well as further increasing the company’s presence in the US market, significantly accelerating the entry of Kardiolitycs VCAST technology into the US market.
James is a highly competitive professional with extensive experience in sales, sales leadership, and business development roles, specializing in quickly building teams that create brand value and drive sales. He has a deep understanding of the cardiac monitoring and medical technology industries. His recent experience includes successfully developing and implementing sales and marketing strategies for digital health and remote patient monitoring services. He has also been extensively involved in strategic planning, building, and managing sales teams.
Prior to joining Medicalgorithmics, James was an Area Director Digital Health and Diagnostic Monitoring at Biotronik. He also worked as a Sales Director at Bardy Diagnostics (now Baxter). In these positions, he had responsibility for managing sales teams and had an active involvement in all aspects of business development.